Join our daily newsletter At The Bell to receive exclusive market insights
- Suda Pharmaceuticals (SUD) was up more than 13 per cent today after receiving a patent from the Australian Patent Office for anagrelide
- The patent will be titled “Prevention and Treatment of Metastatic Disease in Thrombocytotic Cancer Patients” and expires in December 2035
- Anagrelide is a U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved drug used to treat blood disorders
- It does this by targeting platelets which are known to increase the spread of cancers and suppress the body’s immune response to the cancerous cells
- Suda is up a steady 11.6 per cent and shares are currently trading for 4.8 cents each
Suda Pharmaceuticals (SUD) was up more than 13 per cent today after receiving a patent from the Australian Patent Office for anagrelide.
The patent will be titled “Prevention and Treatment of Metastatic Disease in Thrombocytotic Cancer Patients” and expires in December 2035.
This approval follows a grant from the Japanese Patent Office in May.
“We are very pleased to add Australia to the list of territories for which we have a granted patent for this new use of anagrelide, the other territories being Europe and Japan,” CEO Dr Michael Baker said.
“In drug development, patents are an important part of the value creation process and this grant in Australia strengthens our ability to maximise value from the anagrelide program,” he added.
Anagrelide is a U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved drug used to treat blood disorders.
It has been shown to lower the number of blood platelets and obstruct the cancerous cell’s movement towards platelet-producing cells. Interestingly, platelets play a key role in facilitating the growth and spread of cancer, as well as suppressing the body’s immune response to cancer.
Additionally, a recently completed study at Covance in the U.K. has identified an oral spray formulation of the drug may be a safer way to deliver anagrelide in patients with solid tumours.
This may reduce any unwanted side effects associated with the current capsule formula.
Suda is up a steady 11.6 per cent and shares are trading for 4.8 cents each at 12:15 pm AEST.
